Has Hypothesis 3 of the Trauma-Resilience Integration Model (TRIM) ever been tested?
Bottom line: No trial has tested Hypothesis 3 of the Trauma-Resilience Integration Model (TRIM), which suggests that psychedelic-assisted therapy outperforms traditional therapy on a validated symptom scale over at least a year.
A scientist sat at a desk, staring at a spreadsheet. They were checking something the psychedelic therapy field had long assumed was true: that psilocybin or MDMA could change lives in a lasting way. But the science, as it turns out, is far from settled. A new study has now looked through the literature and found something unexpected: no trial has tested the most important claim of the Trauma-Resilience Integration Model (TRIM). And the longest follow-up in any published trial is just six months.

The Claim That Never Got Tested
In 2026, a research team proposed a hypothesis that never made it to print. The Trauma-Resilience Integration Model (TRIM), proposed by Krieger, suggests that psychedelic-assisted therapy — whether with psilocybin or MDMA — outperforms traditional therapy on a validated symptom scale, and that this benefit lasts for at least a year.
This claim has shown up in talks, press releases, and even some journals, but never in a published, peer-reviewed trial. The TRIM team called it Hypothesis 3 — the one they considered the most important.
But here’s the problem: no trial in the published literature has tested it. That’s the finding of a pre-registered audit of all the MDMA- and psilocybin-assisted therapy trials that have been published. The study didn’t collect new data, didn’t do a meta-analysis, and didn’t aim to prove or disprove the hypothesis. Instead, it asked a simple question: has any trial ever met the basic requirements to test Hypothesis 3?
The answer is no.
The Three Requirements That No Trial Met
To test Hypothesis 3, a trial must do three things. First, it must compare psychedelic-assisted therapy with a traditional therapy — not just a placebo or no treatment. Second, it must use a validated symptom scale to measure outcomes. Third, it must have a controlled follow-up of at least 12 months.
None of the published trials have met all three of these criteria. Some used a traditional comparator but didn’t follow up for a year. Others used a validated scale but didn’t compare to traditional therapy. A few had long follow-ups but skipped the comparator. No trial did all three.
This is a big deal. Without a proper test, we can’t say for sure whether psychedelic therapy is better than traditional therapy — or even if it’s better in the short term. The best we can say is that some trials show promise, but they don’t meet the standards of a real test.
The Longest Follow-Up Is Just Six Months
The study also looked for the longest controlled follow-up in the literature. The answer: six months. That’s the maximum duration of any trial that used a traditional comparator and had a controlled follow-up. Some studies reported outcomes at 12 months, but those were often uncontrolled — meaning they didn’t compare the psychedelic group to a traditional therapy group. Without a comparator, it’s hard to tell if the improvement was due to the therapy or just time passing.
This is a problem. Most of the literature on psychedelic therapy focuses on short-term outcomes — weeks or months. But the TRIM hypothesis claims the benefit lasts for a year. Without a trial that actually tests that, we can’t know if the effect is real or just temporary.
What This Means for the Field
The study’s findings are a wake-up call. The psychedelic therapy field has been moving fast, with new trials and results coming out all the time. But if the most important hypothesis — that psychedelic therapy is better than traditional therapy in the long term — hasn’t been tested, then the field is still in a state of uncertainty.
This isn’t just about academic rigor. It’s about real people. Patients are being offered psychedelic therapy, and they’re hoping for real change. But without proper evidence, we risk making promises that can’t be fulfilled.
The study also highlights a broader issue: the lack of standardized methods for testing psychedelic therapy. Different trials use different comparators, different outcome scales, and different follow-up periods. This makes it hard to compare results and draw meaningful conclusions.
Frequently Asked Questions
Q: Why is Hypothesis 3 so important?
A: Because it’s the central claim of the TRIM model, which suggests that psychedelic-assisted therapy is not just a short-term intervention but a lasting solution to trauma. If it’s true, it could change how we think about mental health treatment.
Q: What’s the difference between a traditional comparator and a placebo?
A: A traditional comparator is another form of therapy, like cognitive behavioral therapy or EMDR. A placebo is a dummy treatment, like a pill with no active ingredient. Comparing to a traditional comparator is more meaningful because it shows whether the psychedelic therapy is better than other established treatments.
Q: Why is a 12-month follow-up important?
A: Because the TRIM hypothesis claims that the benefit lasts for at least a year. Without a follow-up of that length, it’s hard to say whether the effect is real or just temporary.
Q: What does this mean for patients?
A: It means patients should be cautious about claims that psychedelic therapy is a cure-all. While some trials show promise, the evidence is still preliminary. More research is needed to understand what works, for whom, and for how long.
Q: Is this study the end of the psychedelic therapy field?
A: No. This study is just a step in the right direction. It highlights the need for more rigorous research, but it doesn’t stop the field from moving forward. The future of psychedelic therapy is still uncertain — but that’s where the real science begins.
Sources
- ¶Has Hypothesis 3 of the Trauma-Resilience Integration Model (TRIM) ever been tested? A pre-registered evidence audit of the MDMA- and psilocybin-assisted therapy randomized trial literature: comparator type, outcome scale, and duration of controlled follow-up
- ¶PRACTICE-ORIENTED EDUCATION – PREREQUISITE FOR THE PREPARATION OF COMPETENT GRADUATES
Educational Disclaimer
This article is for informational and educational purposes only. It is not medical advice, mental health advice, diagnosis, treatment guidance, or a recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may suggest. Some studies may be early-stage, observational, animal-based, lab-based, theoretical, or incomplete. Always consult a qualified professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.